VITRISA THERAPEUTICS INC has a total of 26 patent applications. It decreased the IP activity by 30.0%. Its first patent ever was published in 2017. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are KAWAOKA YOSHIHIRO, THE PIRBRIGHT INST and NAPAJEN PHARMA INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 10 | |
#2 | United States | 6 | |
#3 | EPO (European Patent Office) | 3 | |
#4 | Canada | 2 | |
#5 | China | 2 | |
#6 | Australia | 1 | |
#7 | United Kingdom | 1 | |
#8 | Hong Kong | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Peptides | |
#5 | Measuring microorganism processes | |
#6 | Combinatorial chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Erickson Carl | 24 |
#2 | Rusconi Christopher P | 24 |
#3 | Mclure Kevin G | 20 |
#4 | Levy Matthew | 8 |
#5 | Hutabarat Renta | 8 |
#6 | Bhowmick Arijit | 6 |
#7 | Quick Ryan | 3 |
#8 | Kevin G Mclure | 2 |
#9 | Carl Erickson | 2 |
#10 | Christopher Rusconi | 2 |
Publication | Filing date | Title |
---|---|---|
WO2019222344A1 | Stem-loop compositions and methods for inhibiting interleukin-8 | |
WO2019210194A1 | Pegylated compositions for ocular use, and methods thereof | |
WO2019210097A1 | Aptamers with stability, potency or half-life for enhanced safety and efficacy | |
WO2019022986A1 | Nucleic acid compositions and methods for inhibiting factor d | |
WO2018148333A1 | Compositions with improved intravitreal half-life and uses thereof | |
WO2018136831A1 | Pseudoknot compositions and methods for inhibiting factor d | |
WO2018136827A1 | Stem-loop compositions and methods for inhibiting factor d | |
EP3414330A1 | Compositions with improved intravitreal half-life and uses thereof | |
EP3405575A1 | Methods for improved aptamer selection | |
CN108934169A | Composition and method for inhibiting factor D |